DUBLIN--(BUSINESS WIRE)--The "Axial Spondyloarthritis (axSpA) - United States Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This 'Axial Spondyloarthritis (axSpA)-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the axSpA, historical, and forecasted epidemiology as well as the axSpA market trends in the United States
The axSpA market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted United States axSpA market size from 2018 to 2030.
The Report also covers current axSpA treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key Findings
- The market size of Axial Spondyloarthritis (axSpA) in the US is expected to increase in 2030 from USD 4,716 million in 2020, at a CAGR of 9.8% for the study period 2018-2030.
- According to analysis, the current treatment market includes conventional therapies, biologics, and Cox Inhibitors.
- The market size generated by Cox Inhibitors in 2020 was estimated to be USD 177 million, which by 2030 is expected to increase. Among all the US potential therapies, the highest market is expected to be captured by Bimekizumab.
Market Insights:
- What was the axSpA market share (%) distribution in 2018 and how it would look like in 2030?
- What would be the axSpA total market size as well as market size by therapies across the Unites States during the forecast period (2021-2030)?
- What are the key findings pertaining to the market across the United States and which country will have the largest axSpA market size during the forecast period (2021-2030)?
- At what CAGR, the axSpA market is expected to grow at the United States level during the forecast period (2021-2030)?
- What would be the axSpA market outlook across the United States during the forecast period (2021-2030)?
- What would be the axSpA market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Key Topics Covered:
1 Key Insights
2 Report Introduction
3 Executive Summary of Axial Spondyloarthritis (axSpA)
4 Disease Background and Overview
4.1 Introduction
4.2 Cause
4.3 Etiology
4.3.1 Endogenous Factors
4.3.2 Exogenous Factors
4.4 Risk Factors
4.4.1 Gender
4.4.2 Family History
4.4.3 Genetic Predisposition
4.4.4 Age
4.5 Signs and symptoms
4.6 Genetics - an insight into the pathogenesis
4.6.1 HLAB27 causing AS
4.6.2 Antigen processing and presentation
4.6.3 IL-17 and type 3 immunity in AS
4.6.4 IL-17
4.6.5 IL-23 signaling
4.6.6 Targeting type-3 immunity in AS
4.7 Biomarkers
4.7.1 Genetic biomarkers
4.7.2 Markers for inflammation
4.7.3 Cartilage Turnover Markers
4.7.4 Other Biomarkers
4.8 Clinical Manifestations
4.8.1 Peripheral arthritis
4.8.2 Enthesitis
4.8.3 Restriction of spinal mobility
4.8.4 Hip and shoulder joints
4.8.5 Dactylitis
4.8.6 Extra-articular locations
4.9 Diagnosis
4.9.1 Blood tests
4.9.2 Imaging tests
4.1 Differential Diagnosis
4.11 Underdiagnoses and Diagnostic Delay
4.12 Diagnostic Criteria
4.13 New York Classification Criteria: Diagnostic Criteria for AS
5 Treatment and Management
5.1 Therapeutic treatment
5.1.1 Therapy
5.1.2 Surgery
5.1.3 Lifestyle and home remedies
5.2 Treatment Guidelines
5.2.1 ASAS-EULAR management recommendations for axial spondyloarthritis
5.2.2 Recommendations for the treatment of axial spondyloarthritis
5.2.3 APLAR axial spondyloarthritis treatment recommendations
6 Epidemiology and Patient Population
6.1 Methodology
6.2 United States
6.2.1 Assumptions and Rationale
6.2.2 Total Prevalent Cases of Axial Spondyloarthritis in the United States
6.2.3 Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States
6.2.4 Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States
6.2.5 Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States
6.2.6 Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States
7 Organizations contributing towards Axial Spondyloarthritis (AxSpA)
8 Patient Journey
9 Case Reports
10 Marketed Products
10.1 Key-cross Competition
10.2 Cimzia (Certolizumab pegol): UCB
10.3 Humira (adalimumab): AbbVie
10.4 Celebrex (celecoxib): Pfizer
10.5 Enbrel (Etanercept): Amgen/Pfizer
10.6 Remicade (Infliximab): Janssen Biotech
10.7 Simponi (Golimumab): Janssen Biotech
10.8 Vimovo (naproxen and esomeprazole magnesium): Pozen
10.9 Cosentyx: Novartis
10.10 Indocin: Iroko Pharmaceuticals
10.11 Naprelan: Syntex Pharmaceuticals
10.12 Rayos (Prednisone): Horizon Pharma
10.13 Taltz (ixekizumab): Eli Lilly and Company
11 Emerging Therapies
11.1 Key Cross Competition
11.2 Tofacitinib: Pfizer
11.3 Bimekizumab: UCB Biopharma
11.4 Ilumya (Tildrakizumab): Sun Pharma Global
11.5 Namilumab: Izana Bioscience
11.6 ILT-101(Interleukin 2): Iltoo Pharma
11.7 Brodalumab (KHK4827): Kyowa Kirin
11.8 Rinvoq (Upadacitinib): AbbVie
11.9 Filgotinib: Galapagos/Gilead
12 Axial Spondyloarthritis (AxSpA): Market Analysis
12.1 Market Methodology
12.2 Attribute Analysis
12.3 Potential of Emerging Therapies and Current therapies
12.4 Key Market Forecast Assumptions
13 United States Market Outlook
13.1 United States Market Size
13.1.1 Total Market Size of Axial Spondyloarthritis in United States
13.1.2 Market Size of Axial Spondyloarthritis by Therapies in United States
14 Unmet Needs
15 Market Drivers
16 Market Barriers
17 SWOT Analysis
18 KOL Views
19 Access and Reimbursement Overview: Axial Spondyloarthritis (AxSpA)
20 Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5h6l2k
